Tilray Inc (NASDAQ:TLRY - Get Free Report)'s stock price traded down 1% during mid-day trading on Tuesday . The company traded as low as $0.43 and last traded at $0.44. 3,715,930 shares were traded during mid-day trading, a decline of 87% from the average session volume of 28,504,874 shares. The stock had previously closed at $0.44.
Wall Street Analyst Weigh In
Several research analysts recently commented on the stock. Canaccord Genuity Group lifted their target price on shares of Tilray from $2.00 to $3.00 and gave the stock a "buy" rating in a report on Monday, January 13th. Roth Capital reiterated a "neutral" rating on shares of Tilray in a research note on Monday, April 14th. Finally, Piper Sandler decreased their target price on Tilray from $2.00 to $1.00 and set a "neutral" rating for the company in a research note on Wednesday, April 9th.
Check Out Our Latest Analysis on Tilray
Tilray Trading Down 3.5 %
The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.58 and a current ratio of 2.54. The company's 50 day moving average is $0.56 and its 200 day moving average is $1.00. The stock has a market capitalization of $429.77 million, a price-to-earnings ratio of -1.42 and a beta of 1.95.
Tilray (NASDAQ:TLRY - Get Free Report) last announced its quarterly earnings data on Tuesday, April 8th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.06). Tilray had a negative net margin of 30.95% and a negative return on equity of 4.40%. The company had revenue of $185.78 million for the quarter, compared to analyst estimates of $213.38 million. On average, research analysts forecast that Tilray Inc will post -0.2 EPS for the current fiscal year.
Institutional Trading of Tilray
Several institutional investors have recently modified their holdings of the company. Lido Advisors LLC bought a new position in Tilray in the fourth quarter worth $28,000. Dudley Capital Management LLC acquired a new position in shares of Tilray in the 4th quarter valued at $29,000. Verdence Capital Advisors LLC bought a new position in shares of Tilray during the 4th quarter worth about $29,000. Ameritas Advisory Services LLC acquired a new stake in shares of Tilray during the 4th quarter valued at about $32,000. Finally, Newman Dignan & Sheerar Inc. increased its stake in Tilray by 61.9% in the fourth quarter. Newman Dignan & Sheerar Inc. now owns 26,150 shares of the company's stock valued at $35,000 after acquiring an additional 10,000 shares during the period. Institutional investors and hedge funds own 9.35% of the company's stock.
Tilray Company Profile
(
Get Free Report)
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
Read More
Before you consider Tilray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray wasn't on the list.
While Tilray currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
